Market Assessment of Therapeutic Coordination Polymers Containing Pharmaceuticals and Bis-Imidazole Linkers for Drug Release Applications

用于药物释放应用的含有药物和双咪唑连接体的治疗性配位聚合物的市场评估

• 批准号: 570983-2022
• 负责人: Vukotic, Vedran
• 金额: $ 1.09万
• 依托单位: University of Windsor
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=728720
• 关键词: Market; Assessment; Therapeutic; Coordination; Polymers

Considerable time and resources are required to develop new pharmaceuticals and make new medical treatments available. Researchers at the University of Windsor have taken an alternative approach by incorporating existing medications into controlled release materials to improve their performance and speed up their development time. The materials developed are referred to as Therapeutic Coordination Polymers (TCPs), and are constructed from a unique combination of three principal components, i) inorganic metal centers, ii) anionic pharmaceuticals, and iii) small organic molecules which can behave as a "linker" joining the metal centers. More specifically, the team developed a series of biodegradable TCPs with various cationic metal ions, non-steroidal anti-inflammatory drugs (NSAIDs), and various alkyl chain length bis-imidazole linkers. TCPs offer several unique advantages as drug release materials including: i) rapid and scalable synthesis ii) highly consistent drug loading iii) high drug uptake ~60-70 wt%, iv) biocompatibility, and v) most importantly, an extreme degree of control over their drug release rate which can be tailored for desired applications. Whether drugs are taken in the form of a pill or implanted after surgery in the form of a small degradable implant, TCPs could impact several different routes of drug administration. Overall, this research program has broad applications in many areas of drug release and has the potential to make a significant economic benefit and health benefit to the lives of Canadians.

需要大量的时间和资源来开发新的药物和提供新的医疗方法。温莎大学的研究人员采取了另一种方法，将现有的药物纳入控释材料中，以提高其性能并加快其开发时间。所开发的材料被称为治疗配位聚合物（TCP），并且由三种主要组分的独特组合构成，i）无机金属中心，ii）阴离子药物，和iii）可以作为连接金属中心的“接头”的小有机分子。更具体地说，该团队开发了一系列具有各种阳离子金属离子，非甾体抗炎药（NSAID）和各种烷基链长度双咪唑连接体的可生物降解TCP。TCP作为药物释放材料提供了几个独特的优点，包括：i）快速和可扩展的合成，ii）高度一致的药物负载，iii）高药物吸收~60-70重量%，iv）生物相容性，以及v）最重要的是，对它们的药物释放速率的极端程度的控制，其可以针对所需的应用进行定制。无论药物是以药丸的形式服用，还是在手术后以小的可降解植入物的形式植入，TCP都可能影响几种不同的给药途径。总的来说，这项研究计划在药物释放的许多领域都有广泛的应用，并有可能为加拿大人的生活带来显着的经济效益和健康效益。